Abstract
With B.1.1.529 SARS-CoV-2 variant’s rapid spread and substantially increased resistance to neutralization by vaccinee and convalescent sera, monoclonal antibodies with potent neutralization are eagerly sought. To provide insight into effective neutralization, we determined cryo-EM structures and evaluated potent receptor-binding domain (RBD) antibodies for their ability to bind and neutralize this new variant. B.1.1.529 RBD mutations altered 16% of the RBD surface, clustering on a ridge of this domain proximal to the ACE2-binding surface and reducing binding of most antibodies. Significant inhibitory activity was retained, however, by select monoclonal antibodies including A19-58.1, B1-182.1, COV2-2196, S2E12, A19-46.1, S309 and LY-CoV1404, which accommodated these changes and neutralized B.1.1.529 with IC50s between 5.1-281 ng/ml, and we identified combinations of antibodies with potent synergistic neutralization. Structure-function analyses delineated the impact of resistance mutations and revealed structural mechanisms for maintenance of potent neutralization against emerging variants.
Summary Sentence We show potent B.1.1.529 neutralization by select antibodies and use EM structures to reveal how potency can be retained.
Competing Interest Statement
T.Z., L.W., J.M., A.P., Y.Z., E.S.Y., W.S., J.R.M, N.J.S., and P.D.K. are inventors on US patent application No. 63/147,419. J.R.M, B.S.G., L.W., Y.Z., and W.S. are inventors on PCT/US2020/063991 and PCT/US2021/020843.